Profile data is unavailable for this security.
About the company
Neurizon Therapeutics Limited is an Australia-based clinical-stage biotechnology company. The Company is engaged in advancing treatments for neurodegenerative diseases. It is developing its lead drug candidate, NUZ-001, for the treatment of Amyotrophic Lateral Sclerosis (ALS), which is the common form of motor neurone disease. ALS treatments for patients while exploring the potential of NUZ-001 for broader neurodegenerative applications. ALS is a devastating neurodegenerative condition that primarily affects nerve cells that control voluntary muscles. Through international collaborations and rigorous clinical programs, it is focused on creating new horizons for patients and families impacted by complex neural disorders.
- Revenue in AUD (TTM)1.88m
- Net income in AUD-16.59m
- Incorporated2000
- Employees52.00
- LocationNeurizon Therapeutics LtdSuite 2, Level 11, 385 Bourke StreetMELBOURNE 3000AustraliaAUS
- Phone+61 39692-7222
- Fax+61 89467-6111
- Websitehttps://www.neurizon.com/
